PAMD-Ch17

PAMD-Ch17 is a polymeric analog of the CXCR4 inhibitor AMD3100 (plerixafor) with a cholesterol modification. It was developed as an anti-leukemic agent and shows cytotoxicity toward both myeloid and lymphoblastic acute leukemia cells, notably T-ALL, while sparing healthy hematopoietic cells. Unlike AMD3100, PAMD-Ch17 mediates its anti-leukemic effects primarily through induction of mitochondrial dysfunction. Specifically, it accumulates in mitochondria, increases mitochondrial superoxide, disrupts mitochondrial membrane potential, decreases ATP production, and overall impairs cellular metabolism, resulting in selective leukemia cell death. This mechanism is distinct from and independent of CXCR4 inhibition, highlighting a novel, mitochondria-targeted strategy for leukemia therapy[1][2][6][5][3].